Argos discontinues troubled trial, delists from Nasdaq

Argos made a series of announcements Thursday that reflect troubles stemming from a challenging 2017. The company has said it will discontinue its lead clinical trial, move from the Nasdaq to an OTC market and has hired a financial advisor to help consider its alternatives. Argos (Nasdaq: ARGS) disclosed Thursday that – based on new interim results – it decided to discontinue its phase 3 ADAPT trial of Rocapuldencel-T for the treatment of metastatic kidney cancer and has notified the U.S. Food…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news